R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 26.45 PLN -1.67% Market Closed
Market Cap: zł611.5m

Operating Margin

-174.5%
Current
Declining
by 9.7%
vs 3-y average of -164.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-174.5%
=
Operating Income
zł-121.8m
/
Revenue
zł69.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-174.5%
=
Operating Income
zł-121.8m
/
Revenue
zł69.8m

Peer Comparison

Country Company Market Cap Operating
Margin
PL
Ryvu Therapeutics SA
WSE:RVU
621.9m PLN
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
238.1B USD
Loading...
US
Danaher Corp
NYSE:DHR
167.3B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
83T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
37.9B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.5B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
277.7B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
38.4B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
29.1B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
20.3B EUR
Loading...

Market Distribution

Lower than 91% of companies in Poland
Percentile
9th
Based on 835 companies
9th percentile
-174.5%
Low
-10 083 900% — -1.5%
Typical Range
-1.5% — 11.7%
High
11.7% — 195 905.3%
Distribution Statistics
Poland
Min -10 083 900%
30th Percentile -1.5%
Median 5.4%
70th Percentile 11.7%
Max 195 905.3%

Ryvu Therapeutics SA
Glance View

Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 186 full-time employees. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.

RVU Intrinsic Value
38.06 PLN
Undervaluation 31%
Intrinsic Value
Price
R
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-174.5%
=
Operating Income
zł-121.8m
/
Revenue
zł69.8m
What is Ryvu Therapeutics SA's current Operating Margin?

The current Operating Margin for Ryvu Therapeutics SA is -174.5%, which is below its 3-year median of -164.7%.

How has Operating Margin changed over time?

Over the last 3 years, Ryvu Therapeutics SA’s Operating Margin has increased from -450.1% to -174.5%. During this period, it reached a low of -450.1% on Sep 30, 2022 and a high of -96% on Jun 30, 2023.

Back to Top